CliffBio
small molecule

YEZTUGO

LENACAPAVIR SODIUM

Loss of exclusivityAugust 2038latest FDA-listed patent expiry
CompanyGilead Sciences →View the full company profile on CliffBio

Drug detail

Brand nameYEZTUGO
Active ingredientLENACAPAVIR SODIUM
StrengthEQ 300MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJune 2025
Marketing statusRX

Listed patents

PatentExpiresType
11267799August 2038substance
10071985August 2037substance, product
9951043February 2034substance, product

Regulatory exclusivity

CodeExpires
NPJune 2028
NCEDecember 2027

More from Gilead Sciences

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

YEZTUGO patent cliff — loss of exclusivity August 2038 | CliffBio